Abstract: An omni wheel, comprising a hub bracket (10) and roller components (20). Each roller component (20) comprises a first roller assembly (21) and a second roller assembly (22); the first roller assembly (21) comprises a roller bracket (211) and a first roller structure; the second roller assembly (22) comprises a second shaft (221) and a second roller structure, and the second shaft (221) comprises a second shaft body (2211) and a limiting portion (2212); and the second shaft body (2211) is connected and locked to a first connection structure (2111) to limit the second roller structure between the limiting portion (2212) and the first connection structure (2111). A moving device is further disclosed. The omni wheel can ensure that second rollers will not shake and oscillate during running of the omni wheel and thus reduce vibrations and noise of the omni wheel, improving the running stability.

Abstract: A data swapping method is provided. The data swapping method is applied to a host. An operating system and a target application are installed on the host. The operating system includes user space. A user interface of the target application is disposed in the user space. The user interface corresponds to one storage device. A specific solution includes: The host obtains a swap request of the target application, and calls, based on the swap request, the user interface to perform an operation on the storage device. The swap request is a swap-in request or a swap-out request. The swap-out request is used to request to write data of the target application from a memory of the host to the storage device. The swap-in request is used to request to write data in the storage device to the memory.

Abstract: The application provides a display substrate, a method for manufacturing the same, and a display device. The display substrate includes a display region and a binding region located at a periphery of the display region. The binding region is provided with a drive circuit pin and a flexible circuit board pin, and a connecting trace for connecting the drive circuit pin and the flexible circuit board pin. The connecting trace includes a first connecting line and a second connecting line connected in parallel, the first connecting line and the second connecting line are in different layers, the first connecting line is between an interlayer insulating layer and a base substrate of the display substrate, the first connecting line and the interlayer insulating layer are separated by a first insulating layer, and the second connecting line is on a side of the interlayer insulating layer away from the base substrate.

Abstract: A display includes a polygonal display region and a plurality of non-display portions. The non-display portions are coupled to side edges of the display region in a one-to-one correspondence. At least two of the non-display portions are bent to a back side of the display region. When the non-display portions bent to the back side include adjacent non-display portions, there is an opening between two adjacent non-display portions.

Abstract: Provided is a multimedia data stream processing method, an electronic device and a storage medium, relating to the field of artificial intelligence, and specifically, to the technical fields of cloud computing, media cloud technology, and the like, which may be applied to scenes such as smart cloud. The multimedia data stream processing method includes: allocating a plurality of sub-streams of a multimedia data stream to a plurality of edge resource nodes, where the multimedia data stream is segmented into a plurality of slices and each of the plurality of sub-streams includes a part of the plurality of slices of the multimedia data stream; and scheduling the plurality of edge resource nodes to provide the plurality of sub-streams of the multimedia data stream for a terminal device.

Abstract: A computing system including a plurality of processing devices configured to execute a Mixture-of-Experts (MoE) layer. The processing devices are configured to execute the MoE layer at least in part by receiving an input tensor including input tokens. Executing the MoE layer further includes computing a gating function output vector based on the input tensor and computing a sparse encoding of the input tensor and the gating function output vector. The sparse encoding indicates one or more destination expert sub-models. Executing the MoE layer further includes dispatching the input tensor for processing at the one or more destination expert sub-models, and further includes computing an expert output tensor. Executing the MoE layer further includes computing an MoE layer output at least in part by computing a sparse decoding of the expert output tensor. Executing the MoE layer further includes conveying the MoE layer output to an additional computing process.

Abstract: The present invention relates to the technical field of medicine and relates to an instant release pharmaceutical preparation of an anticoagulant and a preparation method therefor. The instant release pharmaceutical preparation of an anticoagulant comprises a vicagrel compound or a pharmaceutically acceptable form thereof, the preparation is a tablet or a capsule, the vicagrel or the pharmaceutically acceptable form thereof is provided at a suitable particle size, and the D90 thereof <50 ?m. With regard to the drug-containing particles obtained by the present invention, a pharmaceutical preparation formed therefrom exhibits rapid release characteristics in an in vitro dissolution test and exhibits considerable advantages in pharmacokinetics in vivo, showing a greater degree (AUC) and rate (Cmax) of drug absorption.

Abstract: The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein X, D, R1 to R4, and R6 to R10 are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

Abstract: The invention provides novel heteroaryl-substituted imidazole derivatives having the general formula (I), and pharmaceutically acceptable salts thereof, wherein A and R1 to R6 are as described herein: Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

Abstract: The present invention discloses a protein regulating nitrogen-use efficiency and yield of a plant and the use thereof. The present invention obtains a transgenic OsTCP19 rice and a rice OsTCP19 mutant by means of a transgenic technique and a CRISPR-Cas9 technique, respectively. Experiments have shown that compared with wild-type rice, the transgenic OsTCP19 rice has a reduced tiller number and a decreased nitrogen response ability, whereas compared with the wild-type rice, the rice OsTCP19 mutant has an increased tiller number. This indicates that the OsTCP19 protein has the function of regulating the plant yield and nitrogen-use efficiency, thus laying the foundation for cultivating varieties with a high yield and a high nitrogen-use efficiency.

Abstract: The invention provides novel imidazole pyrazole derivatives having the general formula (I), and pharmaceutically acceptable salts thereof, wherein R1-R7 are as described herein: Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

Abstract: The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R9 and p are as described herein: Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

Abstract: The invention provides novel imidazole pyrazole derivatives having the general formula (I), and pharmaceutically acceptable salts thereof, wherein A and R1-R7 are as described herein: Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

Abstract: This application provides an e-cigarette vaporizer and an e-cigarette. The e-cigarette vaporizer includes an outer housing including an open end and an end cap arranged at the open end, where a liquid storage cavity and a sealing base configured to seal the liquid storage cavity are provided in the outer housing; a sealing ring is arranged between the end cap and the outer housing; a vaporization cavity is provided between the sealing ring and the sealing base, and the liquid substrate is vaporized in the vaporization cavity to generate aerosol released to the vaporization cavity; and a plurality of liquid storage grooves configured to adsorb and hold aerosol condensate are provided in the vaporization cavity. The e-cigarette vaporizer uses the liquid storage groove for absorbing the condensate through the capillary action, and prevents the condensate from being taken out along with inhaling airflow during inhaling.

Abstract: The invention provides novel imidazopyrazine derivatives having the general formula (I), and pharmaceutically acceptable salts thereof, wherein X1 to X4, R1 to R5, R8 to R10, A, and L1 are as described herein: Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

Abstract: The invention provides novel imidazopyrazine derivatives having the general formula (I), wherein Rx and R3 to R5 are as described herein: or pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

Abstract: The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein X, D, R1 to R4, and R6 to R10 are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

Abstract: The present invention relates to the technical field of medicine and relates to an instant release pharmaceutical preparation of an anticoagulant and a preparation method therefor. The instant release pharmaceutical preparation of an anticoagulant comprises a vicagrel compound or a pharmaceutically acceptable form thereof, the preparation is a tablet or a capsule, the vicagrel or the pharmaceutically acceptable form thereof is provided at a suitable particle size, and the D90 thereof <50 ?m. With regard to the drug-containing particles obtained by the present invention, a pharmaceutical preparation formed therefrom exhibits rapid release characteristics in an in vitro dissolution test and exhibits considerable advantages in pharmacokinetics in vivo, showing a greater degree (AUC) and rate (Cmax) of drug absorption.

Abstract: Disclosed in the present invention are a pyrazolo [1,5-a]pyrimidine derivative having a structure of formula (I), a pharmaceutical composition comprising the compound of formula (I), and use of the compound in the preparation of a medicament for preventing or treating diseases associated with tropomyosin receptor kinases, in particular for preventing or treating cancers associated with tropomyosin receptor kinases. Each substituent in formula (I) has the same definition as that in the description.

Abstract: Provided are novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R4, m, n, and p are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.